General population studies have reported that 7 to 8% adults currently have chronic neuropathic pain, where the reported incidence is of 8 cases per 1,000 individuals per year. In the U.K. alone, 26% individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030. Anticonvulsant pregabalin (Lyrica, Pfizer) is among the most widely spread drug for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously report cost-benefit to insurers and regulatory bodies. In terms of market competition, the existing brands are being continually expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion
The report titled Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery).
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global peripheral neuropathy market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global peripheral neuropathy market. This report concludes with company profiles section that highlights major information about the key players engaged in global peripheral neuropathy market. In-depth competitive environment analysis and historical (2021) market size data are also provided in the report.
Pharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizures medications occupies maximum share in peripheral market around 41% in 2016, followed by antidepressants and pain killers. Anti-seizures medication include Gabapentin and Pregabalin, that are used as first line of treatment, with Pregabalin occupying major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.
At present, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high research trials on peripheral neuropathy in the country and high prices of the medication generating high revenue. Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV/AIDS.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery).
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global peripheral neuropathy market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global peripheral neuropathy market. This report concludes with company profiles section that highlights major information about the key players engaged in global peripheral neuropathy market. In-depth competitive environment analysis and historical (2021) market size data are also provided in the report.
Pharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizures medications occupies maximum share in peripheral market around 41% in 2016, followed by antidepressants and pain killers. Anti-seizures medication include Gabapentin and Pregabalin, that are used as first line of treatment, with Pregabalin occupying major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.
At present, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high research trials on peripheral neuropathy in the country and high prices of the medication generating high revenue. Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV/AIDS.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Peripheral Neuropathy market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Peripheral Neuropathy market and their expected impact during the forecast period.
Market Segmentation
Treatment Type
- Pharmacological Therapies
- Pain Relievers
- Tramadol
- Oxycodone
- Cylcooxgenase Inhibitors
- Corticosteroid
- Anti-seizure medication sction
- Gabapentin
- Pregabalin
- Antidepressants
- Amitriptyline
- Doxepin
- Nortriptyline
- Duloxetine
- Venlafaxine
- Non-Pharmacological Therapies
- Transcutaneous electrical nerve stimulation
- Plasma exchange and intravenous immune globulin
- Others(Physical Therapy and Surgery)
Key Questions Answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Peripheral Neuropathy market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Peripheral Neuropathy market?
- Which is the largest regional market for Peripheral Neuropathy market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Peripheral Neuropathy market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Peripheral Neuropathy market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Peripheral Neuropathy Market
2.2. Global Peripheral Neuropathy Market, By Treatment Type, 2021 (US$ Million)
2.3. Global Peripheral Neuropathy Market, By Geography, 2021 (US$ Million)
2.4. Impact of Covid 19
2.5. Attractive Investment Proposition by Geography, 2021
2.6. Competitive Analysis
2.6.1. Market Positioning of Key Peripheral Neuropathy Market Vendors
2.6.2. Strategies Adopted by Peripheral Neuropathy Market Vendors
2.6.3. Key Industry Strategies
3. Peripheral Neuropathy Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Peripheral Neuropathy Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat Of Substitutes
3.6.4. Threat Of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
4. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Pharmacological Therapies
4.3.1.1. Pain Relievers
4.3.1.1.1. Tramadol
4.3.1.1.2. Oxycodone
4.3.1.1.3. Cylcooxgenase Inhibitors
4.3.1.1.4. Corticosteroid
4.3.1.2. Anti-seizure medicationsction
4.3.1.2.1. Gabapentin
4.3.1.2.2. Pregabalin
4.3.1.3. Antidepressants
4.3.1.3.1. Amitriptyline
4.3.1.3.2. Doxepin
4.3.1.3.3. Nortriptyline
4.3.1.3.4. Duloxetine
4.3.1.3.5. Venlafaxine
4.3.1.4. Non-Pharmacological Therapies
4.3.1.4.1. Transcutaneous electrical nerve stimulation
4.3.1.4.2. Plasma exchange and intravenous immune globulin
4.3.1.4.3. Others(Physical Therapy and Surgery)5. North America Peripheral Neuropathy Market, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
5.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
5.3.1.North America
5.3.1.1. U.S.
5.3.1.2. Canada
5.3.1.3. Rest of North America
6. UK and European Union Peripheral Neuropathy Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
6.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
6.3.1.UK and European Union
6.3.1.1. UK
6.3.1.2. Germany
6.3.1.3. Spain
6.3.1.4. Italy
6.3.1.5. France
6.3.1.6. Rest of Europe
7. Asia Pacific Peripheral Neuropathy Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
7.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
7.3.1.Asia Pacific
7.3.1.1. China
7.3.1.2. Japan
7.3.1.3. India
7.3.1.4. Australia
7.3.1.5. South Korea
7.3.1.6. Rest of Asia Pacific
8. Latin America Peripheral Neuropathy Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
8.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
8.3.1.Latin America
8.3.1.1. Brazil
8.3.1.2. Mexico
8.3.1.3. Rest of Latin America
9. Middle East and Africa Peripheral Neuropathy Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
9.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
9.3.1.Middle East and Africa
9.3.1.1. GCC
9.3.1.2. Africa
9.3.1.3. Rest of Middle East and Africa
10. Company Profile
10.1. Abbott Laboratories
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Portfolio
10.1.4. Strategic Initiatives
10.2. Bristol Myers Squibb
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.4. Strategic Initiatives
10.3. Cipla Limited
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.4. Strategic Initiatives
10.4. Eli Lilly and Company
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Portfolio
10.4.4. Strategic Initiatives
10.5. GlaxoSmithKline plc.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Portfolio
10.5.4. Strategic Initiatives
10.6. Lupin Limited
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.4. Strategic Initiatives
10.7. Merck and Co. Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Portfolio
10.7.4. Strategic Initiatives
10.8. Novartis
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.4. Strategic Initiatives
10.9. Pfizer Inc.
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Portfolio
10.9.4. Strategic Initiatives
10.10. Dr. Reddy's Laboratories
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Portfolio
10.10.4. Strategic Initiatives
List of Figures
Figure 1. Global Peripheral Neuropathy Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Peripheral Neuropathy Market: Quality Assurance
Figure 5 Global Peripheral Neuropathy Market, By Treatment Type, 2021
Figure 6 Global Peripheral Neuropathy Market, By Geography, 2021
Figure 7 Global Peripheral Neuropathy Market, By Treatment Type, 2021 Vs 2030, %
Figure 8 U.S. Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 9 Canada Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 10 Rest of North America Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 11 UK Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 12 Germany Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 13 Spain Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 14 Italy Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 15 France Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 16 Rest of Europe Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 17 China Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 18 Japan Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 19 India Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 20 Australia Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 21 South Korea Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 22 Rest of Asia Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 23 Brazil Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 24 Mexico Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 25 Rest of Latin America Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 26 GCC Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 27 Africa Peripheral Neuropathy Market (US Million), 2020 - 2030
Figure 28 Rest of Middle East and Africa Peripheral Neuropathy Market (US Million), 2020 - 2030
List of Tables
Table 1 Global Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
Table 2 Global Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
Table 3 Global Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
Table 4 Global Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
Table 5 Global Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
Table 6 Global Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
Table 7 North America Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
Table 8 North America Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
Table 9 North America Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
Table 10 North America Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
Table 11 North America Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
Table 12 North America Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
Table 13 UK and European Union Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
Table 14 UK and European Union Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
Table 15 UK and European Union Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
Table 16 UK and European Union Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
Table 17 UK and European Union Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
Table 18 UK and European Union Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
Table 19 Asia Pacific Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
Table 20 Asia Pacific Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
Table 21 Asia Pacific Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
Table 22 Asia Pacific Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
Table 23 Asia Pacific Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
Table 24 Asia Pacific Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
Table 25 Latin America Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
Table 26 Latin America Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
Table 27 Latin America Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
Table 28 Latin America Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
Table 29 Latin America Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
Table 30 Latin America Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
Table 31 Middle East and Africa Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
Table 32 Middle East and Africa Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
Table 33 Middle East and Africa Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
Table 34 Middle East and Africa Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
Table 35 Middle East and Africa Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
Table 36 Middle East and Africa Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
Companies Mentioned
- Abbott Laboratories
- Bristol Myers Squibb
- Cipla Limited
- Eli Lilly and Company
- GlaxoSmithKline plc.
- Lupin Limited
- Merck and Co. Inc.
- Novartis
- Pfizer Inc.
